Short Interest in Aeterna Zentaris Inc. (NASDAQ:AEZS) Expands By 171.9%

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) was the target of a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 17,400 shares, a growth of 171.9% from the May 15th total of 6,400 shares. Based on an average trading volume of 9,400 shares, the days-to-cover ratio is presently 1.9 days. Approximately 0.6% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Aeterna Zentaris in a research note on Sunday. They issued a “sell” rating on the stock.

Aeterna Zentaris Stock Performance

Shares of AEZS opened at $6.67 on Thursday. The stock has a market capitalization of $8.07 million, a P/E ratio of -0.45 and a beta of 1.60. Aeterna Zentaris has a 1 year low of $5.44 and a 1 year high of $12.80. The company’s fifty day moving average is $8.15 and its two-hundred day moving average is $7.97.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) earnings per share (EPS) for the quarter. Aeterna Zentaris had a negative return on equity of 83.45% and a negative net margin of 760.32%.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.